Connection

David Cole to Mice

This is a "connection" page, showing publications David Cole has written about Mice.
Connection Strength

0.861
  1. Effect of administration timing of postchemotherapy granulocyte colony-stimulating factor on host-immune cell recovery and CD8+ T-cell response. J Immunotoxicol. 2016 11; 13(6):784-792.
    View in: PubMed
    Score: 0.057
  2. Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells. Cancer Immunol Immunother. 2015 May; 64(5):539-49.
    View in: PubMed
    Score: 0.052
  3. Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with cyclophosphamide. Cell Immunol. 2012 Mar-Apr; 276(1-2):67-74.
    View in: PubMed
    Score: 0.043
  4. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host. J Am Coll Surg. 2012 Apr; 214(4):700-7; discussion 707-8.
    View in: PubMed
    Score: 0.042
  5. Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer. J Surg Res. 2012 Aug; 176(2):359-66.
    View in: PubMed
    Score: 0.041
  6. Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. J Immunol. 2010 Feb 15; 184(4):1737-47.
    View in: PubMed
    Score: 0.037
  7. Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo. Cell Immunol. 2010; 261(2):134-43.
    View in: PubMed
    Score: 0.036
  8. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J Immunol. 2009 Feb 15; 182(4):2030-40.
    View in: PubMed
    Score: 0.034
  9. The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into na?ve recipient mice. Vaccine. 2009 Jan 22; 27(4):549-57.
    View in: PubMed
    Score: 0.034
  10. Loss of T cell-mediated antitumor immunity after construct-specific downregulation of retrovirally encoded T-cell receptor expression in vivo. Cancer Gene Ther. 2009 Feb; 16(2):171-83.
    View in: PubMed
    Score: 0.033
  11. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother. 2007 Jan; 30(1):40-53.
    View in: PubMed
    Score: 0.030
  12. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine. 2006 Jun 12; 24(24):5119-32.
    View in: PubMed
    Score: 0.028
  13. Bystander effect contributes to the antitumor efficacy of CaSm antisense gene therapy in a preclinical model of advanced pancreatic cancer. Mol Ther. 2006 Feb; 13(2):357-65.
    View in: PubMed
    Score: 0.027
  14. Establishing a murine pancreatic cancer CaSm model: up-regulation of CaSm is required for the transformed phenotype of murine pancreatic adenocarcinoma. Mol Ther. 2005 Mar; 11(3):363-72.
    View in: PubMed
    Score: 0.026
  15. Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity. J Immunol. 2003 Feb 01; 170(3):1209-17.
    View in: PubMed
    Score: 0.023
  16. The cancer-associated Sm-like oncogene: a novel target for the gene therapy of pancreatic cancer. Surgery. 2000 Aug; 128(2):353-60.
    View in: PubMed
    Score: 0.019
  17. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination. Clin Cancer Res. 1999 May; 5(5):1173-82.
    View in: PubMed
    Score: 0.017
  18. Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. Cancer Res. 2018 06 01; 78(11):3067-3074.
    View in: PubMed
    Score: 0.016
  19. Characterization of a sustained-release delivery system for combined cytokine/peptide vaccination using a poly-N-acetyl glucosamine-based polymer matrix. Clin Cancer Res. 1997 Jun; 3(6):867-73.
    View in: PubMed
    Score: 0.015
  20. Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis. Cancer Immunol Immunother. 2017 Jun; 66(6):737-751.
    View in: PubMed
    Score: 0.015
  21. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model. J Hepatol. 2017 01; 66(1):75-85.
    View in: PubMed
    Score: 0.014
  22. Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance. Cancer Immunol Res. 2016 09 02; 4(9):799-811.
    View in: PubMed
    Score: 0.014
  23. Lack of p53 Augments Antitumor Functions in Cytolytic T Cells. Cancer Res. 2016 09 15; 76(18):5229-5240.
    View in: PubMed
    Score: 0.014
  24. IL-2Ra mediates temporal regulation of IL-2 signaling and enhances immunotherapy. Sci Transl Med. 2015 Oct 28; 7(311):311ra170.
    View in: PubMed
    Score: 0.014
  25. Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Ra Dependent. Cancer Immunol Res. 2015 Dec; 3(12):1364-74.
    View in: PubMed
    Score: 0.013
  26. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors. J Control Release. 2015 Oct 28; 216:103-10.
    View in: PubMed
    Score: 0.013
  27. Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling. Clin Cancer Res. 2015 Jun 01; 21(11):2546-57.
    View in: PubMed
    Score: 0.013
  28. The inducible costimulator augments Tc17 cell responses to self and tumor tissue. J Immunol. 2015 Feb 15; 194(4):1737-47.
    View in: PubMed
    Score: 0.013
  29. Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors. J Control Release. 2014 Mar 28; 178:79-85.
    View in: PubMed
    Score: 0.012
  30. Activity of drug-loaded tumor-penetrating microparticles in peritoneal pancreatic tumors. Curr Cancer Drug Targets. 2014; 14(1):70-8.
    View in: PubMed
    Score: 0.012
  31. G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses. J Hematol Oncol. 2013 Oct 01; 6:75.
    View in: PubMed
    Score: 0.012
  32. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr; 20(4):222-8.
    View in: PubMed
    Score: 0.011
  33. A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. J Immunol. 2012 Aug 15; 189(4):1627-38.
    View in: PubMed
    Score: 0.011
  34. CD8(+) T cells sabotage their own memory potential through IFN-?-dependent modification of the IL-12/IL-15 receptor a axis on dendritic cells. J Immunol. 2012 Apr 15; 188(8):3639-47.
    View in: PubMed
    Score: 0.011
  35. CaSm (LSm-1) overexpression in lung cancer and mesothelioma is required for transformed phenotypes. Am J Respir Cell Mol Biol. 2008 Jun; 38(6):671-8.
    View in: PubMed
    Score: 0.008
  36. Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model. Cancer Immunol Immunother. 2008 Apr; 57(4):563-72.
    View in: PubMed
    Score: 0.008
  37. CaSm-mediated cellular transformation is associated with altered gene expression and messenger RNA stability. Cancer Res. 2005 Jul 15; 65(14):6228-36.
    View in: PubMed
    Score: 0.007
  38. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother. 2005 May-Jun; 28(3):220-8.
    View in: PubMed
    Score: 0.007
  39. Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine. J Immunol. 2004 May 01; 172(9):5159-67.
    View in: PubMed
    Score: 0.006
  40. Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2). Vaccine. 2003 Jun 02; 21(19-20):2318-28.
    View in: PubMed
    Score: 0.006
  41. CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell. J Immunol. 2003 Mar 01; 170(5):2582-9.
    View in: PubMed
    Score: 0.006
  42. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response. J Immunother. 2001 Sep-Oct; 24(5):420-9.
    View in: PubMed
    Score: 0.005
  43. Identification of a T-cell receptor from a therapeutic murine T-cell clone. J Immunother. 1997 Jul; 20(4):247-55.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.